CLN-619

A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Near Add Your Location

Sorting 13 by

Memorial Sloan Kettering Cancer Center
New York, NY
Fully Open
  • Accepting patients
  • Show Principal Investigator
The University of Texas Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
  • Accepting patients
  • Show Principal Investigator
Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
  • Accepting patients
Memorial Sloan Kettering Nassau
Uniondale, NY
Limited Activities
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Basking Ridge
Basking Ridge, NJ
Limited Activities
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Bergen
Montvale, NJ
Fully Open
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Monmouth
Middletown, NJ
Fully Open
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Commack
Commack, NY
Fully Open
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Westchester
West Harrison, NY
Fully Open
  • Accepting patients
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.